- View VALNEVA starts Phase I trial of VLA1553 for Chikungunya Currently reading
Novel Drugs & Emergent Therapeutics | Phase I clinical trial to assess the safety and immunogenicity of its VLA1553 vaccine for Chikungunya
Published in Source Journal:13 June 2023
Type of article: Summary of Novel Drug Research
MedED Catalogue Reference: MIND001
Catalogue Tabs: Infectious Diseases | Chikungunya | Phase 1 Clinical Trial
Sources: Valneva Press Release, Clinical Trials Arena
Valneva has initiated a Phase I clinical trial to assess the safety and immunogenicity of its VLA1553 vaccine for Chikungunya, a viral disease transmitted by mosquitoes. The randomized trial, conducted in the US, will evaluate three different doses of the vaccine in approximately 120 healthy adults. The study will also assess antibody persistence and re-vaccination at six and 12 months to determine the vaccine's potential efficacy. Initial data from the trial is expected to be available early next year. Valneva aims to develop a single-dose vaccine that provides long-lasting protection against Chikungunya, offering safety for immunization in both adults and children.
Chikungunya is a viral disease caused by the chikungunya virus, transmitted by Aedes mosquitoes. It leads to symptomatic illness in a high percentage of people, causing fever, joint and muscle pain, headache, nausea, rash, and chronic joint pain. The virus can cause large outbreaks, affecting a significant portion of the population in areas where it is present. Travellers to endemic regions, such as parts of Africa, Southeast Asia, and the Americas, are at risk. The virus has spread to over 110 countries, with more than three million reported cases in the Americas alone. The economic impact of chikungunya is significant, and the medical and economic burden is expected to grow as the virus spreads further. Currently, there are no preventive vaccines or effective treatments available, making chikungunya a major public health threat.
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet ( Press Release)
VALNEVA starts Phase I trial of VLA1553 for Chikungunya ( Clinical Trial Arena
Disclaimer
This article is compiled from a variety of resources researched and compiled by the contributor. It is in no way presented as an original work. Every effort has been made to correctly attribute quotes and content. Where possible all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.
